CDK4 and breast carcinoma: All 3 drugs have again showed a statistically significant PFS benefit compared to AI monotherapy in this setting.13-15 ET with a CDK4/6i has largely become the standard of care initial therapy for patients with advanced HR+/Her2− breast cancer.